Chlorothricin | 34707-92-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: Chlorothricin
• 英文别名: (1S,3R,6R,7E,13R,16S,17S,21R,22R)-17-[(2R,4R,5S,6R)-5-[(2S,4R,5R,6R)-4-(3-chloro-6-methoxy-2-methylbenzoyl)oxy-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-28-hydroxy-3,22-dimethyl-23,26-dioxo-24,27-dioxapentacyclo[23.2.1.01,6.013,22.016,21]octacosa-4,7,14,25(28)-tetraene-4-carboxylic acid
• CAS: 34707-92-1
• 化学式: C₅₀H₆₃ClO₁₆
• 分子量: 955.494
• InChiKey: WUXHQHDSSKBJFH-DELKKKATSA-N

物化性质

• 熔点：
  206-207°
• 沸点：
  1050.8±65.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于乙醇；可溶于甲醇；可溶于DMSO；可溶于二甲基甲酰胺

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  67
• 可旋转键数：
  9
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  223
• 氢给体数：
  4
• 氢受体数：
  16

文献信息

• METHOD FOR PREPARING PROPARGYLIC ALCOHOL CATALYZED BY 2-MORPHOLINOISOBORNANE-10-THIOL
  申请人：UANG Biing-Jiun

  公开号：US20110295042A1

  公开（公告）日：2011-12-01

  A method for preparing a propargylic alcohol catalyzed by 2-morpholinoisobornane-10-thiol (MITH) is disclosed, which includes reacting R 1 CHO with R 2 CCH in the presence of R 3 ZnR 4 and MITH, wherein each of R 1 , R 2 , R 3 , and R 4 , independently, is optionally substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkylsilyl, heterocycloalkyl, heterocycloalkenyl, aryl, aryloxy, or heteroaryl. The method can give enantioenriched propargylic alcohols with good enantioselective at low loading of MITH.

  揭示了一种由2-吗啉基异冰片烷-10-硫醇（MITH）催化制备丙炔醇的方法，该方法包括在R3ZnR4和MITH的存在下，将R1CHO与R2CCH反应，其中R1、R2、R3和R4中的每一个，独立地，可以是可选取代的烷基、烯基、环烷基、环烯基、烷基硅基、杂环烷基、杂环烯基、芳基、芳氧基或杂芳基。该方法可以在MITH的低负载下提供具有良好对映选择性的对映富集的丙炔醇。
• [EN] ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTIMICROBIENS/D'ADJUVANTS ET PROCÉDÉS ASSOCIÉS
  申请人：DENOVAMED INC

  公开号：WO2012116452A1

  公开（公告）日：2012-09-07

  Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula la: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided.

  一般情况下，根据公式Ia提供抗微生物和/或辅助化合物，其中E和R1-11具有本文中描述的含义；以及它们的前药和药用盐。还提供其他公式和使用方法。
• Chloroquine combination drugs and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20070060499A1

  公开（公告）日：2007-03-15

  This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

  这项发明揭示了氯喹偶联活性药剂的组合物，包括其制备方法。先前的技术已经表明，以足够高浓度给予氯喹作为游离药物，可以增强细胞内体内各种药剂从细胞内体释放到细胞质中。这些组合物的目的是在传递活性药剂的相同部位提供受控量的氯喹，从而减少所需的总剂量。这些组合物包括将氯喹物质直接或通过各种药用载体物质偶联到活性药剂。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以产生治疗效果的物质。这些组合物还可以包括用于携带和释放活性药剂以用于治疗或其他医疗用途的生物可降解连接。该发明还揭示了与靶向分子偶联的载体组合物，用于将氯喹物质和活性药剂定位传递到它们的作用部位。
• Chloroquine coupled nucleic acids and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20060040879A1

  公开（公告）日：2006-02-23

  This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the nucleic acid needs to be released, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a nucleic acid directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing nucleic acids for therapeutic or other medical uses. The invention also discloses nucleic acid carrier compositions that are coupled to targeting molecules for targeting the delivery of nucleic acids to their site of action.

  本发明披露了制备氯喹偶联核酸组合物的组成和方法。先前的研究表明，以足够高的浓度给予氯喹作为自由药物，可以增强细胞内体内各种物质从内体泡中释放到细胞质中。这些组合物的目的是在核酸需要释放的同一位置提供受控量的氯喹，从而降低所需的总剂量。该组合物包括直接或通过各种药物载体物质偶联的氯喹物质和核酸。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以达到治疗效果的物质。该组合物还可以包括生物可降解连接来携带和释放用于治疗或其他医疗用途的核酸。本发明还披露了偶联到靶向分子的核酸载体组合物，用于将核酸传递到其作用位置。
• TARGETING CONJUGATES COMPRISING ACTIVE AGENTS ENCAPSULATED IN CYCLODEXTRIN-CONTAINING POLYMERS
  申请人：Gnaim Jallal M.

  公开号：US20100226987A1

  公开（公告）日：2010-09-09

  A targeting conjugate is provided comprising an active agent, one or more residues of a cyclodextrin (CD)-containing polymer and a biorecognition molecule. The polymer is preferably a peptide or a polypeptide comprising at least one amino acid residue containing a functional side group to which at least one of the CD residues is linked covalently; the biorecognition molecule is covalently bonded directly or via a spacer to the polymer backbone of the CD-containing polymer; and the active agent is noncovalently encapsulated within the cavity of the cyclodextrin residues and/or entrapped within the polymer matrix of the CD-containing polymer.

  提供了一种靶向共轭物，包括活性剂、一个或多个含有环糊精（CD）的聚合物残基和生物识别分子。该聚合物最好是肽或多肽，包括至少一个氨基酸残基，其含有一个功能性侧基，至少一个CD残基与之共价连接；生物识别分子通过空间连接或直接与CD含聚合物的聚合物骨架共价键合；活性剂非共价地包装在环糊精残基的空腔内和/或被CD含聚合物的聚合物基质所包裹。